Abstract
Early menopause and related vaginal atrophy is a well known side-effect of hormone adjuvant treatment in breast cancer patients, particularly during aromatase-inhibitors therapy. Due to estrogens contra-indication, proper therapy for such symptom remains often an inadequately addressed clinical problem. After an accurate assessment of the risk/benefit ratio, vaginal low-dose estrogen treatment (better with estriol) [corrected] may have a role in controlling vaginal atrophy in selected and informed breast cancer women.
MeSH terms
-
Administration, Intravaginal
-
Antineoplastic Agents, Hormonal / administration & dosage
-
Antineoplastic Agents, Hormonal / adverse effects
-
Aromatase Inhibitors / administration & dosage
-
Aromatase Inhibitors / adverse effects*
-
Atrophy / chemically induced
-
Atrophy / drug therapy
-
Atrophy / pathology
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / epidemiology
-
Estriol / administration & dosage*
-
Estrogens / administration & dosage
-
Female
-
Humans
-
Neoplasm Recurrence, Local / epidemiology
-
Risk Factors
-
Survivors
-
Tamoxifen / administration & dosage
-
Tamoxifen / adverse effects*
-
Vagina / drug effects
-
Vagina / pathology*
-
Vaginal Diseases* / chemically induced
-
Vaginal Diseases* / drug therapy
-
Vaginal Diseases* / pathology
Substances
-
Antineoplastic Agents, Hormonal
-
Aromatase Inhibitors
-
Estrogens
-
Tamoxifen
-
Estriol